INVESTIGADORES
BOTTERO Daniela
artículos
Título:
Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
Autor/es:
GAILLARD M.E.; BOTTERO D; ERREA A; ORMAZABAL M; ZURITA E; MORENO G; RUMBO M; CASTUMA C.; BARTEL E; FLORES D; VANDERLEY,PETER; VANDERARK, A; HOZBOR D
Revista:
VACCINE
Editorial:
ELSEVIER SCI LTD
Referencias:
Lugar: Amsterdam; Año: 2014
ISSN:
0264-410X
Resumen:
Despite high vaccination coverage rates, pertussis continues to be a
global concern, with increased incidence widely noted. The current
pertussis epidemiologic situation has been mainly attributed to waning
immunity and pathogen adaptation. To improve the disease control, a new
generation of vaccines capable to overcome those weaknesses associated
to the current vaccines need to be developed. Previously we have
demonstrated that the outer membrane vesicles obtained from the
recombinant Bordetella pertussis strain expressing PagL enzyme
(OMVs(BpPagL)) are good vaccine candidates to protect against pertussis.
In this work the OMVs(BpPagL) formulated with diphtheria and tetanus
toxoids (Tdap(OMVsBpPagL)) was used to evaluate its capacity to offer
protection against Argentinean clinical isolates and to induce long-term
immunity. To these aims BALB/c mice were immunized with
Tdap(OMVsBpPagL) and challenged with sublethal doses of the clinical
isolate Bp106 selected as a representative circulating isolate.
Comparisons with a current commercial Tdap vaccine used at a dose in
which pertussis toxin level was equivalent to that of Tdap(OMVsBpPagL)
were performed. With the normalized doses of both vaccines we observed
that Tdap(OMVsBpPagL) protected against the clinical isolate infection,
whereas current commercial Tdap vaccine showed little protection against
such pathogen. Regarding long-term immunity we observed that the
Tdap(OMVsBpPagL) protective capacity against the recommended WHO
reference strain persisted at least 9 months. In agreement with these
results Tdap(OMVsBpPagL) induced Th1 and Th2 immune response. In
contrast, commercial Tdap induced Th2 but weak Th1 responses. All
results presented here showed that Tdap(OMVsBpPagL) is an interesting
formulation to be considered for the development of novel acellular
multi-antigen vaccine.